STAT

Long miles, lonely roads: In rural Texas, dying at home means little is easy

“You drive down roads, you might hit a wild hog, it’s so dark. Some people will flicker their lights out in the country so we can find them.”

HASKELL COUNTY, Texas — To get to the house where Shawn Jordan wants to die, you drive a hypnotic road along miles of furrowed cotton fields, gnarly mesquite trees, low-to-the-ground cactus, and cattle perpetually in search of food.

This iconic land of open spaces and oil pumps, where the Panhandle meets west Texas, is where the 43-year-old came home after a car accident he said should have killed him. He’s since had his paralyzed legs amputated, and survived seven MRSA infections.

He’s been in hospice care since that last infection, because he knows the eighth could be his last. And he wants to spend his remaining time here, with family, surrounded by the rocking horse and toys of his toddler grandson, as well as emblems of the working west — antique spurs and ranch hooks on the wall, tin stars, and a saddle in a corner by the door. It’s his country. It’s home.

“I wanted to see everybody one last time, if I was going to pass away,” Jordan said about the moment he decided to go into hospice. “It was going to be in a familiar environment, in my environment. This was going to be a lot more comfortable.”

Read more: Reimagining hospice care —

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks